Nasemann T, Wassilew S W
Br J Vener Dis. 1979 Apr;55(2):121-2. doi: 10.1136/sti.55.2.121.
Type-specific vaccines containing heat-inactivated herpes simplex hominis virus type 1 or 2 have been developed for the treatment of herpes simplex genitalis. When patients with recurrent herpes genitalis were treated with the type 2 vaccine the clinical course of the disease improved and the eruption-free interval was extended. In severe cases, especially in permanent genital herpes, the concurrent administration of vaccine and immunoglobulin concentrates improved the clinical course of the disease. Antibody titres and the in-vitro stimulation of lymphocytes with phytohaemagglutinin or herpes simplex hominis virus antigens remained constant during administration of the vaccine.
已研发出含有热灭活人单纯疱疹病毒1型或2型的型特异性疫苗，用于治疗单纯疱疹性生殖器炎。复发性单纯疱疹性生殖器炎患者接受2型疫苗治疗后，疾病的临床病程得到改善，无疹间歇期延长。在严重病例中，尤其是在慢性生殖器疱疹中，同时给予疫苗和免疫球蛋白浓缩物可改善疾病的临床病程。在疫苗接种期间，抗体滴度以及用植物血凝素或人单纯疱疹病毒抗原进行的淋巴细胞体外刺激保持不变。
